Novo Nordisk A/S (NVO) Primary Owner to Open Obesity Drug Incubators Across Europe

Novo Nordisk A/S (NYSE:NVO) is among the Best Pharmaceutical Stocks.

On June 19, Novo Nordisk A/S (NYSE:NVO)’s primary owner, the Novo Nordisk Foundation, reported that it is launching research incubators across Europe to speed up obesity and diabetes drug development. The foundation said it is funding a pan-European program targeting cardiometabolic diseases. It will commit up to DKK 450 million (EUR 60.2 million) over six years, opening its first lab in London this month, followed by sites in Italy and Germany.

Novo Nordisk Foundation’s CEO Mads Krogsgaard Thomsen said the effort plans to convert “extraordinary science” into drug discovery projects, addressing a gap where academic breakthroughs fail to reach patients. Professor Graham Cooke of Imperial College London said many discoveries lack support to progress commercially and that London’s selection is a reflection of its strong ecosystem.

Pixabay/Public Domain

The foundation said the BioInnovation Institute will lead the initiative. Its CEO, Jens Nielsen, commented that its scale “supports research and innovation that can benefit patients and society.”

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company. It works in the discovery, development, manufacturing, and marketing of pharmaceutical products. It functions through the Diabetes and Obesity Care and Rare Disease segments.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.